Company intelligence / Profile preview

Axelife

Saint-Nicolas-de-Redon, Pays de la Loire, Franceaxelife.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Axelife has developed the pOpmètre®, a CE-marked Class IIa medical device that provides rapid and non-invasive measurement of arterial stiffness using pulse wave velocity. The device enables early detection and prevention of cardiovascular risks by providing actionable data such as vascular age. It has been clinically validated and supported by over 30 scientific publications on arterial stiffness measurement.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Drug pipeline

1 asset

pOpmètre

Commercial

Indications: Cardiovascular disease, Arterial stiffness

Partnerships

Supported by leading French and international cardiologists; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on Axelife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axelife.

Explore the full profile